Page last updated: 2024-12-04

propiolactone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Propiolactone: Disinfectant used in vapor form to sterilize vaccines, grafts, etc. The vapor is very irritating and the liquid form is carcinogenic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2365
CHEMBL ID1200627
CHEBI ID49073
MeSH IDM0017758

Synonyms (154)

Synonym
beta propiolactone
propanolide
57-57-8
nsc-21626
3-propanolide
3-propiolactone
.beta.-proprolactone
betaprone
wln: t4ovtj
.beta.-propiolactone
hydracrylic acid, .beta.-lactone
nsc21626
.beta.-propionolactone
propiolactone .beta.-
propiolactone
hydracrylic acid .beta.-lactone
1,3-propiolactone
2-oxetanone
propionic acid, .beta.-lactone
3-hydroxypropionic acid, lactone
.beta.-propanoic acid lactone
propanoic acid, .beta.-lactone
BPL ,
KBIO1_001003
DIVK1C_001003
SPECTRUM_000216
IDI1_001003
beta-propiolactone
hydracylic acid, .beta.lactone
D05630
betaprone (tn)
propiolactone (usan/inn)
oxetan-2-one
inchi=1/c3h4o2/c4-3-1-2-5-3/h1-2h
NCGC00090802-01
propiolactona
hydracrylic acid beta-lactone
propiolactonum
beta-propionolactone
3-hydroxypropionic acid beta-lactone
beta-propanoic acid lactone
betapron
beta-lactone hydracrylic acid
CHEBI:49073 ,
beta-propiolakton
propiolattone [dcit]
propionolactone
propiolactone, beta-
einecs 200-340-1
nsc 21626
propiolactona [inn-spanish]
ai3-24257
epa pesticide chemical code 010901
ccris 536
beta-propiolakton [czech]
b-propiolactone
hsdb 811
propiolactonum [inn-latin]
caswell no. 709
propanoic acid, 3-hydroxy-, beta-lactone
beta-proprolactone
3-hydroxypropionic acid lactone
propiolactone [usan:inn:ban]
oxetanone
propionic acid, 3-hydroxy-, beta-lactone
brn 0001360
beta-propiolactone, grade ii, >=90%
NCGC00090802-03
NCGC00090802-02
KBIO2_000696
KBIO2_003264
KBIO2_005832
KBIOSS_000696
KBIOGR_001888
NINDS_001003
SPECTRUM2_001982
SPBIO_002163
SPECTRUM4_001274
SPECTRUM1503234
HMS2092P12
CHEMBL1200627
HMS503I07
HMS1922K19
C19297
beta-hydroxypropionic acid lactone
H0168
pharmakon1600-01503234
nsc-758422
nsc758422
dtxsid8021197 ,
tox21_111026
cas-57-57-8
dtxcid801197
CCG-39865
6rc3zt4hb0 ,
unii-6rc3zt4hb0
propiolattone
ec 200-340-1
5-17-09-00003 (beilstein handbook reference)
FT-0622937
AM20020040
propiolactone [hsdb]
propiolactone [mart.]
beta-propiolactone [iarc]
.beta.-propiolactone [mi]
propiolactone [orange book]
propiolactone [usan]
propiolactone [inn]
AKOS015906936
oxetan-2one
propionic acid, 3-hydroxy-, .beta.-lactone
.beta.-propriolactone
.beta.-lactone hydracrylic acid
propanoic acid, 3-hydroxy-, .beta.-lactone
2-oxooxetane
.beta.-propiolakton
3-hydroxypropionic acid .beta.-lactone
2-oxacyclobutanone
AB00052333_02
mfcd00005169
DB09348
3-propiolacetone
3-hydroxy-beta-lactone
?-propiolactone
sr-05000001970
SR-05000001970-1
SBI-0051797.P002
hydracrylic acid ss-lactone
BCP07366
Q420715
AT19319
A936942
25037-58-5
EN300-68177
BP-31191
Z1089877620
beta-propiolactone (iarc)
hydracrylic acid,beta,lactone
propiolactone (mart.)
betraprone
hydracrylic acid, b-lactone
3-hydroxypropionic acid, b-lactone
b-propionolactone
propiolactonum (inn-latin)
3-hydroxypropionic acid, beta-lactone
propionic acid, 3-hydroxy-,beta-lactone
propanilide
beta-pl
hydroacrylic acid, beta-lactone
propanoic acid, 3-hydroxy-,beta-lactone
propiolactona (inn-spanish)
propionic acid 3-hydroxy-beta-lactone
hydracrylic acid, beta-lactone
hydracrylic acid, beta lactone

Research Excerpts

Overview

beta-propiolactone (BPL) is a widely used chemical inactivator of several viruses. It is an alkylating agent which reacts with nucleophilic reagents including nucleic acids and proteins.

ExcerptReferenceRelevance
"β-propiolactone (BPL) is a widely used chemical inactivator of several viruses."( Inactivation of SARS-CoV-2 by β-propiolactone causes aggregation of viral particles and loss of antigenic potential.
Gupta, D; Harshan, KH; Parthasarathy, H; Reddy, S; Sah, V; Tandel, D; Vedagiri, D, 2021
)
1.46
"Betapropiolactone (BPL) is a disinfectant, effective against bacteria, fungi and viruses."( Validation of betapropiolactone (BPL) as an inactivant for infectious bovine rhinotracheitis (IBR) virus.
Kamaraj, G; Lakshmi Narasu, M; Srinivasan, VA, 2008
)
1.16
"beta-propiolactone (BPL) is an alkylating agent which reacts with many nucleophilic reagents including nucleic acids and proteins. "( Inactivation of DNA by beta-propiolactone.
Morgeaux, S; Perrin, P, 1995
)
1.1

Effects

ExcerptReferenceRelevance
"beta-Propiolactone (beta PL) has been tested on preimplantation mouse embryos for possible genotoxic effects. "( The genotoxic effect of beta-propiolactone on mammalian oocytes.
Egozcue, J; Estop, AM; Santaló, J, 1987
)
1.08

Treatment

beta-propiolactone (beta-PL) treatment has been evaluated for its ability to inactivate 10(3.5) chimpanzee infectious doses (CID50) of the Hutchinson strain of hepatitis non-A, non-B virus. beta-Propiolactsone vapor treatment of vaccine production facilities has been shown to be approximately 90% effective in the elimination of large quantities of Simian virus-40 (SV(40)

ExcerptReferenceRelevance
"beta-Propiolactone vapor treatment of vaccine production facilities has been shown to be approximately 90% effective in the elimination of large quantities of Simian virus-40 (SV(40)). "( BETA-PROPIOLACTONE DECONTAMINATION OF SIMIAN VIRUS-40 AS DETERMINED BY A RAPID FLUORESCENT-ANTIBODY ASSAY.
GOULET, NR; LEVINE, SI; LIU, OC, 1965
)
1.27
"beta-Propiolactone-treated and UV-irradiated rat serum was injected into rats to investigate its ability to generate new immunogenic determinants. "( [Tolerance of beta-propiolactone-treated and UV-irradiated rat serum].
Sonneborn, HH; Stephan, W, 1980
)
1.1
"beta-propiolactone treatment induced a reduction in complement activation, tested "in vivo", without significant loss of biological activity."( Effect of beta-propiolactone treatment on the complement activation mediated by equine antisera.
Guidolin, R; Higashi, HG; Marcelino, JR; Morais, JF; Stephano, MA; Yamaguchi, IK,
)
0.94
"beta-propiolactone (beta-PL) treatment has been evaluated for its ability to inactivate 10(3.5) chimpanzee infectious doses (CID50) of the Hutchinson strain of hepatitis non-A, non-B virus (HNANBV). "( Inactivation of the Hutchinson strain of hepatitis non-A, non-B virus in intravenous immunoglobulin by beta-propiolactone.
Brotman, B; Dichtelmüller, H; Huima, T; Prince, AM; Stephan, W, 1988
)
1
"beta-Propiolactone-treated (BPL-T) homologous serum albumin caused anaphylaxis in guinea pigs with a frequency and severity equal to that of guinea pigs inoculated with human albumin. "( Sensitization induced in guinea pigs with beta-propiolactone-treated serum albumin: experimental evidence for the cause of allergic reactions in humans receiving human diploid cell rabies vaccines.
Elisberg, BL; Fitzgerald, EA; Levenbook, IS; Merritt, BA, 1986
)
1.04

Toxicity

ExcerptReferenceRelevance
" A specific role of the virus in this toxic syndrome can be demonstrated when heparin is employed to circumvent intravascular coagulation and fibrinogen loss."( The pathogenesis of Vaccinia virus toxicity. I. The role of virus-platelet interaction.
Campbell, WG; Cassel, WA; Sottnek, HM, 1975
)
0.25
" Hyperimmunoglobulin (HIg) preparations from cold sterilized plasma, offering protection against hepatitis B and NANB are also safe regarding HTLV-III virus transmission, even though these preparations may contain HTLV-III antibody titers up to 1:1000."( Virus safety of beta-propiolactone treated plasma preparations. Clinical experiences.
Brackmann, HH; Heinrich, D; Lissner, R; Stephan, W; Sugg, U, 1987
)
0.59
" No vaccine-related serious adverse reaction was reported in these studies."( Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine.
Atmar, RL; Briggs, DJ; Chin, JE; Famula, M; Froeschle, JE; Jones, RL; Lang, J; Matthews, JS; Moeller, L; Pardalos, J; Sanders, R, 2001
)
0.31
" The incidence of early adverse reactions (all mild) was similar for both antivenoms (15% and 24%; P>0."( Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without beta-propiolactone, in the treatment of Bothrops asper bites in Colombia.
Alzate, C; Arrieta, AB; Arroyo, Y; Ayala, S; Barona, J; Conrado, LL; Córdoba, E; Díaz, A; Fabra, PE; Fernández, D; Fernández, J; Gutiérrez, JM; León, G; López, M; Meza, JJ; Mosquera, D; Núñez, V; Ospina, CE; Otero, R; Paniagua, CA; Quintana, JC; Ramírez, E; Ramírez, P; Rodríguez, V; Rojas, G; Silva, JF; Theakston, RD; Toro, MF; Warrell, DA, 2006
)
0.54
" Carbopol proved to be more immunogenic than aluminium hydroxide and was totally safe when administered to young goslings and breeders alike."( Safety and efficacy of an inactivated Carbopol-adjuvanted goose haemorrhagic polyomavirus vaccine for domestic geese.
Claverys, C; Gelfi, J; Guerin, JL; Pappalardo, M; Peralta, B, 2010
)
0.36
" These results support the idea of a safe production of recombinant proteins using adenoviral vectors."( Biosafety evaluation of recombinant protein production in goat mammary gland using adenoviral vectors: preliminary study.
Espinoza, AS; Moltó, MP; Pedroso, MS; Pose, AG; Rodríguez, ES; Zamora, PA, 2012
)
0.38
" As work with the virus is recommended to be performed at biosafety level 3, validated methods to effectively inactivate the virus to enable the safe study of RNA, DNA, and protein from infected cells are also needed."( Propagation, Inactivation, and Safety Testing of SARS-CoV-2.
Basler, CF; Jureka, AS; Silvas, JA, 2020
)
0.56
"The primary safety outcome was the combined adverse reactions 7 days after each injection, and the primary immunogenicity outcome was neutralizing antibody response 14 days after the whole-course vaccination, which was measured by a 50% plaque reduction neutralization test against live severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."( Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Chen, W; Du, J; Duan, K; Gao, X; Guo, J; Guo, W; Huang, L; Huang, S; Li, X; Lu, J; Meng, Z; Pan, A; Peng, C; Shen, S; Shi, Z; Wan, X; Wang, Q; Wang, W; Wang, X; Wang, Y; Wang, Z; Wu, C; Xia, S; Xie, Z; Yang, X; Yang, Y; You, W; Yuan, Z; Zhang, H; Zhang, L; Zhang, W; Zhang, Y; Zhao, D; Zhou, W, 2020
)
0.56
" The 7-day adverse reactions occurred in 3 (12."( Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Chen, W; Du, J; Duan, K; Gao, X; Guo, J; Guo, W; Huang, L; Huang, S; Li, X; Lu, J; Meng, Z; Pan, A; Peng, C; Shen, S; Shi, Z; Wan, X; Wang, Q; Wang, W; Wang, X; Wang, Y; Wang, Z; Wu, C; Xia, S; Xie, Z; Yang, X; Yang, Y; You, W; Yuan, Z; Zhang, H; Zhang, L; Zhang, W; Zhang, Y; Zhao, D; Zhou, W, 2020
)
0.56
"In this interim report of the phase 1 and phase 2 trials of an inactivated COVID-19 vaccine, patients had a low rate of adverse reactions and demonstrated immunogenicity; the study is ongoing."( Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Chen, W; Du, J; Duan, K; Gao, X; Guo, J; Guo, W; Huang, L; Huang, S; Li, X; Lu, J; Meng, Z; Pan, A; Peng, C; Shen, S; Shi, Z; Wan, X; Wang, Q; Wang, W; Wang, X; Wang, Y; Wang, Z; Wu, C; Xia, S; Xie, Z; Yang, X; Yang, Y; You, W; Yuan, Z; Zhang, H; Zhang, L; Zhang, W; Zhang, Y; Zhao, D; Zhou, W, 2020
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" of traditional Chinese herbal medicines and its confusable varieties, second derivative FTIR spectroscopy was used combined with statistics."( [Direct identification of Ophiogon japonicus (Thunb.)Ker-Gawl. from its confusable varieties by second derivative FTIR spectroscopy combined with statistics].
Cheng, CG; Pan, YJ; Sun, CR, 2004
)
0.32

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" This technique, which assesses biological activity of immunoglobulin, is useful in comparing preparations, and may help to establish appropriate dosage and frequency for intravenous immunoglobulin replacement therapy."( Assessment of biological activity of immunoglobulin preparations by using opsonized micro-organisms to stimulate neutrophil chemiluminescence.
Cole, PJ; Munro, CS; Stanley, PJ, 1985
)
0.27
" VOAspi-PbetaPL film inhibited cell proliferation in a dose-response manner and induced formation of approximately half of the thiobarbituric acid reactive substances (TBARS), an index of lipid peroxidation."( A vanadium/aspirin complex controlled release using a poly(beta-propiolactone) film. Effects on osteosarcoma cells.
Alessandrini, JL; Cortizo, AM; Cortizo, MS; Etcheverr, SB, 2001
)
0.55
" None of the dosage regimens of either antivenom used guaranteed resolution of venom-induced coagulopathy within 6 h, nor did they prevent recurrences."( Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without beta-propiolactone, in the treatment of Bothrops asper bites in Colombia.
Alzate, C; Arrieta, AB; Arroyo, Y; Ayala, S; Barona, J; Conrado, LL; Córdoba, E; Díaz, A; Fabra, PE; Fernández, D; Fernández, J; Gutiérrez, JM; León, G; López, M; Meza, JJ; Mosquera, D; Núñez, V; Ospina, CE; Otero, R; Paniagua, CA; Quintana, JC; Ramírez, E; Ramírez, P; Rodríguez, V; Rojas, G; Silva, JF; Theakston, RD; Toro, MF; Warrell, DA, 2006
)
0.54
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
propan-3-olide
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AR proteinHomo sapiens (human)Potency25.11510.000221.22318,912.5098AID743054
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency12.58930.001318.074339.8107AID926; AID938
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency0.25120.316212.443531.6228AID924
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency53.08040.000627.21521,122.0200AID651741
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
Integrin beta-3Homo sapiens (human)Potency0.25120.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency0.25120.316211.415731.6228AID924
Nuclear receptor ROR-gammaHomo sapiens (human)Potency47.30790.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (83)

Processvia Protein(s)Taxonomy
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (30)

Processvia Protein(s)Taxonomy
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (32)

Processvia Protein(s)Taxonomy
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (396)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990259 (65.40)18.7374
1990's44 (11.11)18.2507
2000's25 (6.31)29.6817
2010's51 (12.88)24.3611
2020's17 (4.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.28 (24.57)
Research Supply Index6.11 (2.92)
Research Growth Index4.53 (4.65)
Search Engine Demand Index87.03 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (1.13%)5.53%
Reviews11 (2.48%)6.00%
Case Studies4 (0.90%)4.05%
Observational0 (0.00%)0.25%
Other423 (95.49%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]